Antibacterial drugs are important for treating infections. But increasingly, bacterial resistance to current drugs — so they don’t work well, or even at all — means new ones are urgently needed. Building on previous work, researchers in ACS Infectious Diseases have demonstrated a potential antibacterial treatment from a modified darobactin, a compound originally from a bacterium. The team reports proof-of-concept animal trials on infections caused by bacteria, including E. coli, that are known to develop drug resistance.

Residential garden produce grown near the Fayetteville Works fluorochemical plant can expose those who consume it to per- and polyfluoroalkyl substances (PFAS), according to a new study conducted by researchers from North Carolina State University, East Carolina University and the Colorado School of Mines.